InVitae (NVTA) Issues Quarterly Earnings Results

InVitae (NYSE:NVTA) issued its quarterly earnings results on Monday. The medical research company reported ($0.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.17), Briefing.com reports. The business had revenue of $25.40 million during the quarter, compared to the consensus estimate of $24.18 million. InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. The business’s quarterly revenue was up 175.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.69) earnings per share.

InVitae (NVTA) traded down $0.75 on Tuesday, hitting $5.54. The stock had a trading volume of 1,136,803 shares, compared to its average volume of 1,021,106. The company has a market capitalization of $333.03 and a PE ratio of -2.26. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.33. InVitae has a 1-year low of $3.80 and a 1-year high of $10.41.

Several research analysts have commented on NVTA shares. Ladenburg Thalmann Financial Services started coverage on InVitae in a research report on Friday, January 5th. They issued a “buy” rating and a $15.00 price target on the stock. Leerink Swann dropped their price target on InVitae from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 16th. Zacks Investment Research downgraded InVitae from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Benchmark dropped their price target on InVitae from $16.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 16th. Finally, BidaskClub downgraded InVitae from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 15th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. InVitae presently has a consensus rating of “Hold” and a consensus price target of $11.00.

TRADEMARK VIOLATION WARNING: “InVitae (NVTA) Issues Quarterly Earnings Results” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/12/invitae-nvta-announces-quarterly-earnings-results-misses-expectations-by-0-23-eps.html.

InVitae Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Earnings History for InVitae (NYSE:NVTA)

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply